Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL

Leukemia

Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3

Leukemia

Shah BD, Cassaday RD, Park JH, Houot R, Logan AC, Boissel N, Leguay T, Bishop MR, Topp MS, O'Dwyer KM, Tzachanis D, Arellano ML, Lin Y, Baer MR, Schiller GJ, Subklewe M, Abedi M, Minnema MC, Wierda WG, DeAngelo DJ, Stiff P, Jeyakumar D, Mao D, Adhikary S, Zhou L, Hadjivassileva T, Damico Khalid R, Ghobadi A, Oluwole OO

doi: 10.1038/s41375-025-02532-7

Lymphoma

Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma

Blood Cancer J

Epperla N, Lucero M, Bailey T, Mirams L, Cheung J, Amet M, Milligan G, Chen L

doi: 10.1038/s41408-024-01195-4

Lymphoma

Real-world outcomes with novel therapies in relapsed/refractory diffuse large B-cell lymphoma

Leuk Lymphoma

Crombie JL, Jun M, Wang T, Mutebi A, Wang A, Chhibber A, Kamalakar R, Ukropec J, Blaedel J, Kalsekar A

doi: 10.1080/10428194.2024.2371472

ASH 2024

Lymphoma

A novel bicistronic CD19/CD22 CAR T-cell therapy is effective and safe in children with relapsed or refractory B-ALL

Lymphoma

Anti-CD19 chimeric antigen receptor T-cell therapy in older patients with relapsed or refractory large B-cell lymphoma: A multicenter study

Am J Hematol

Tun AM, Patel RD, St-Pierre F, Ouchveridze E, Niu A, Thordardottir T, Obasi J, Rosenthal A, Pophali PA, Fenske TS, Karmali R, Ahmed S, Johnston PB

doi: 10.1002/ajh.27381

EHA 2024

Lymphoma

STARGLO: Glofitamab combination therapy shows significant benefits in patients with relapsed/refractory diffuse large B-cell lymphoma

Further Publications

Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study

Lancet Haematol

Dupuis J, Bachy E, Morschhauser F, Cartron G, Fukuhara N, Daguindau N, Casasnovas RO, Snauwaert S, Gressin R, Fox CP, d'Amore FA, Staber PB, Tournilhac O, Bouabdallah K, Thieblemont C, André M, Rai S, Ennishi D, Gkasiamis A, Nishio M, Fornecker LM, Delfau-Larue MH, Sako N, Mule S, de Leval L, Gaulard P, Tsukasaki K, Lemonnier F

doi: 10.1016/S2352-3026(24)00102-9

Lymphoma

Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated With R-GemOx: A Multicenter Cohort Study

Am J Hematol

Yamshon S, Koff JL, Larson MC, Kahl BS, Casulo C, Lossos IS, Haddadi S, Stanchina M, Chihara D, Ayers A, Habermann TM, Wang Y, Khurana A, Nowakowski GS, Reicks TW, Farooq U, Link BK, Cohen JB, Martin P, Li J, Shewade A, Batlevi CL, Lo-Rossi A, Fox D, Masaquel A, Mun Y, Cerhan JR, Flowers CR, Maurer MJ, Nastoupil LJ

doi: 10.1002/ajh.27630

Lymphoma

Chimeric antigen receptor copies in cell-free DNA predict relapse in aggressive B-cell lymphoma patients treated with CAR T-cell therapy

Br J Haematol

de la Iglesia-San Sebastián I, López-Esteban M, Bastos-Oreiro M, Fernández de Córdoba-Oñate S, Gutierrez M, Carbonell D, Bailén R, Gómez-Centurión I, Fernández-Caldas P, Castilla L, Anguita J, Kwon M, García-Sanz R, Buño I, Martínez-Laperche C

doi: 10.1111/bjh.19916

Related content

Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3

Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma

Real-world outcomes with novel therapies in relapsed/refractory diffuse large B-cell lymphoma

A novel bicistronic CD19/CD22 CAR T-cell therapy is effective and safe in children with relapsed or refractory B-ALL

Anti-CD19 chimeric antigen receptor T-cell therapy in older patients with relapsed or refractory large B-cell lymphoma: A multicenter study

STARGLO: Glofitamab combination therapy shows significant benefits in patients with relapsed/refractory diffuse large B-cell lymphoma

Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study

Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated With R-GemOx: A Multicenter Cohort Study

Chimeric antigen receptor copies in cell-free DNA predict relapse in aggressive B-cell lymphoma patients treated with CAR T-cell therapy